Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025

Core Insights - Dermata Therapeutics, Inc. announced the presentation of an abstract from its Phase 3 STAR-1 clinical study of XYNGARI™ for treating moderate-to-severe acne at the EADV Congress 2025 in Paris [1] Group 1: Clinical Study Details - The abstract titled "Once Weekly Topical Treatment with DMT310 Demonstrates Significant and Early Onset of Effect in Patients with Moderate to Severe Acne Vulgaris - Results from the STAR-1 Phase 3 Study" will be presented [1] - The full abstract will be released on September 16, 2025, at 10:00 PM (PST) [1]